Cyprus Health Insurance Organization announces end of Efluelda vaccine supply

On November 9, 2026, the Health Insurance Organization (HIO) of Cyprus initiated a new ordering cycle for seasonal influenza vaccines for doctors participating in the Genuinely Unified Health System (GeSY). The organization confirmed that stocks of the high-dose Efluelda vaccine are officially exhausted and no longer available for procurement. Consequently, the current ordering window, which runs from November 9 through November 12, is exclusively dedicated to the Vaxigrip TIV vaccine.

The national vaccination program for the 2026-2027 period involved the procurement of 170,000 total doses, consisting of 60,000 Efluelda units and 110,000 Vaxigrip TIV units. The Efluelda vaccine was prioritized during the initial phase for elderly patients, while Vaxigrip TIV was designated for the broader population. Doctors must submit their orders for the remaining Vaxigrip TIV supply via a specified electronic link.

The distribution of these vaccines is managed by a private contractor under an agreement with the Ministry of Health. Due to this arrangement, the HIO clarified that it cannot influence or guarantee specific delivery timelines for the orders placed by medical professionals. This operational structure remains in place as the healthcare system continues its seasonal vaccination efforts.